Record NNP B-NP O
date NN I-NP O
: : O O
2097-12-04 CD O B-DATE
SECTIONS NNS B-NP O
OF IN B-PP O
THIS DT B-NP O
NOTE JJ I-NP O
WERE NNP I-NP O
CREATED NNP I-NP O
WITH IN B-PP O
A DT B-NP O
'COPY JJ I-NP O
AND CC I-NP O
PASTE' JJ I-NP O
ACTION. NNP I-NP O
THESE NNP I-NP O
SECTIONS NNP I-NP O
MAY NNP I-NP O
NOT NNP I-NP O
HAVE NNP I-NP O
COPIED NNP I-NP O
COMPLETELY NNP I-NP O
. . I-NP O
PLEASE NNP I-NP O
USE NNP I-NP O
CAUTION NNP I-NP O
WHEN WRB B-ADVP O
RENDERING NNP B-NP O
CLINICAL NNP I-NP O
JUDGMENT NNP I-NP O
BASED NNP I-NP O
ON IN B-PP O
THE DT B-NP O
INFORMATION NN I-NP O
IN IN B-PP O
THIS NNP B-NP O
NOTE. NNP I-NP O
Internal NNP B-NP O
Medicine NNP I-NP O
Medical NNP B-NP O
Student NNP I-NP O
Admission NNP I-NP O
Note NNP I-NP O
PATIENT NNP B-NP O
: : O O
Rojas NNP B-NP I-PATIENT
, , O I-PATIENT
Alaina NNP B-NP I-PATIENT
MRN NNP B-NP O
: : O O
7269058 CD O B-MEDICALRECORD
ADMIT NNP B-NP O
DATE NNP I-NP O
: : O O
12/04/2097 CD O B-DATE
PCP NNP B-NP O
: : O O
Dr. NNP B-NP O
Ruba NNP I-NP B-DOCTOR
Neil NNP I-NP I-DOCTOR
, , O O
Dr. NNP B-NP O
William NNP I-NP B-DOCTOR
Aquino NNP I-NP I-DOCTOR
(onc NNP I-NP O
) -RRB- O O
CONTACT NN B-NP O
: : O O
Claire NNP B-NP B-PATIENT
Ortega NNP I-NP I-PATIENT
( -LRB- I-NP O
daughter NN I-NP O
, , O O
660-750-9168 CD B-NP B-PHONE
) -RRB- O O
CODE NNP B-NP O
STATUS NNP I-NP O
: : O O
Full NNP B-NP O
SOURCE NNP B-NP O
: : O O
Previous JJ B-NP O
notes NNS I-NP O
CHIEF JJ B-NP O
COMPLAINT NNP I-NP O
: : O O
Mechanical NNP B-NP O
Fall NNP I-NP O
HISTORY NN B-NP O
OF IN B-PP O
PRESENT JJ B-NP O
ILLNESS NNS I-NP O
: : O O
( -LRB- B-NP O
Patient NNP I-NP O
was VBD B-VP O
taken VBN I-VP O
to TO B-PP O
surgery NN B-NP O
immediately RB B-ADVP O
upon IN B-PP O
arriving VBG B-VP O
to TO B-PP O
floor NN B-NP O
) -RRB- O O
Per IN B-PP O
PCP NNP B-NP O
: : O O
Ms. NNP B-NP O
Rojas NNP I-NP B-PATIENT
is VBZ B-VP O
a DT B-NP O
87 CD I-NP B-AGE
-year-old JJ I-NP O
woman NN I-NP O
with IN B-PP O
a DT B-NP O
PMH NNP I-NP O
of IN B-PP O
metastatic JJ B-NP O
pancreatic JJ I-NP O
cancer NN I-NP O
recently RB B-ADVP O
diagnosed VBN B-VP O
s/p NN B-NP O
1 CD I-NP O
dose NN I-NP O
of IN B-PP O
gemcitabine NN B-NP O
( -LRB- I-NP O
on IN B-PP O
11/14 CD B-NP B-DATE
) -RRB- I-NP O
, , I-NP O
DM NNP I-NP O
, , I-NP O
HTN NNP I-NP O
, , I-NP O
and CC I-NP O
CRI NNP I-NP O
who WP B-NP O
presents VBZ B-VP O
s/p JJ B-NP O
mechanical JJ I-NP O
fall NN I-NP O
at IN B-PP O
home NN B-NP O
resulting VBG I-NP O
in IN B-PP O
a DT B-NP O
right JJ I-NP O
hip NN I-NP O
fracture NN I-NP O
. . O O
Patient NNP B-NP O
was VBD B-VP O
in IN B-PP O
USOH NNP B-NP O
until IN B-PP O
the DT B-NP O
day NN I-NP O
of IN B-PP O
admission NN B-NP O
when WRB B-ADVP O
she PRP B-NP O
got VBD B-VP O
up RP B-PRT O
out IN B-NP O
of IN B-PP O
a DT B-NP O
chair NN I-NP O
to TO B-VP O
reach VB I-VP O
for IN B-PP O
her PRP$ B-NP O
glasses NNS I-NP O
, , O O
and CC O O
then RB O O
went VBD B-VP O
to TO I-VP O
sit VB I-VP O
back RB B-ADVP O
down RB B-ADVP O
and CC O O
missed VBD B-VP O
the DT B-NP O
chair NN I-NP O
and CC O O
fell VBD B-VP O
to TO B-PP O
the DT B-NP O
ground NN I-NP O
. . O O
Per IN B-PP O
the DT B-NP O
PCP NNP I-NP O
, , O O
the DT B-NP O
patient NN I-NP O
had VBD B-VP O
no DT B-NP O
presyncopal NN I-NP O
symptoms NNS I-NP O
and CC O O
did VBD B-VP O
not RB I-VP O
lose VB I-VP O
consciousness NN B-NP O
. . O O
ED VBN B-NP O
COURSE NNP I-NP O
: : O O
T NNP B-NP O
97.8 CD I-NP O
P NNP I-NP O
56 CD I-NP O
BP NNP I-NP O
: : O O
156/59 CD B-NP O
RR NN I-NP O
: : O O
20 CD B-NP O
97 CD I-NP O
% NN I-NP O
RA NNP I-NP O
Foreshortened VBN B-NP O
RLExt NN I-NP O
Needs NNS B-NP O
basal JJ B-NP O
insulin NN I-NP O
PMH/PSH NNP B-NP O
: : O O
( -LRB- B-NP O
1 CD I-NP O
) -RRB- I-NP O
Pancreatic NNP I-NP O
cancer NN I-NP O
a DT B-NP O
. . I-NP O
10/30/2097 CD I-NP B-DATE
, , O O
patient NN B-NP O
presented VBD B-VP O
to TO B-PP O
PCP NNP B-NP O
with IN B-PP O
dark JJ B-NP O
urine NN I-NP O
and CC O O
progressively RB B-VP O
increasing VBG I-VP O
FBSGs NNS B-NP O
( -LRB- B-NP O
h/o NN I-NP O
DM) NN I-NP O
. . O O
She PRP B-NP O
was VBD B-VP O
admitted VBN I-VP O
for IN B-PP O
evaluation NN B-NP O
of IN B-PP O
hyperglycemia NN B-NP O
and CC O O
was VBD B-VP O
noted VBN I-VP O
to TO I-VP O
be VB I-VP O
jaundiced VBN I-VP O
with IN B-PP O
elevated JJ B-NP O
LFTs NNP I-NP O
. . I-NP O
RUQ NNP I-NP O
U/S NNP I-NP O
showed VBD B-VP O
CBD NNP B-NP O
dilatation NN I-NP O
with IN B-PP O
hypoechoic JJ B-NP O
mass NN I-NP O
near IN B-PP O
head NN B-NP O
of IN B-PP O
pancreas NNS B-NP O
measuring VBG B-VP O
4.1x5x5.5cm CC O O
b NN B-NP O
. . B-VP O
11/03/2097 CD B-NP B-DATE
, , O O
ERCP NNP B-NP O
showed VBD B-VP O
3cm IN B-PP O
distal JJ B-NP O
bile NN I-NP O
duct NN I-NP O
stricture NN I-NP O
that WDT B-NP O
was VBD B-VP O
stented VBN I-VP O
. . O O
LFTs NNP B-NP O
trended VBD B-VP O
down IN B-PP O
s/p NN B-NP O
biliary NN I-NP O
stenting VBG B-VP O
. . B-NP O
Biopsy NNP I-NP O
obtained VBD B-VP O
under IN B-PP O
EUS NNP B-NP O
guidance NN I-NP O
showed VBD B-VP O
pancreatic JJ B-NP O
adenocarcinoma NN I-NP O
. . O O
CT '' O O
scan NN B-NP O
revealed VBD B-VP O
pulmonary JJ B-NP O
nodules NNS I-NP O
, , O O
likely JJ B-NP O
metastatic JJ I-NP O
disease NN I-NP O
c. NN B-NP O
11/14/2097 CD I-NP B-DATE
, , O O
treated VBN B-VP O
with IN B-PP O
1st JJ B-NP O
dose NN I-NP O
of IN B-PP O
25 CD B-NP O
% NN I-NP O
dose NN I-NP O
gemcitabine NN I-NP O
( -LRB- B-VP O
given VBN I-VP O
CKD) NNP B-NP O
, , O O
course NN B-NP O
s/p VB B-VP O
chemotx NN B-NP O
c/b NN I-NP O
fatigue NN I-NP O
, , O O
rash NN B-NP O
, , O O
worsening VBG B-VP O
renal JJ B-NP O
function NN I-NP O
and CC I-NP O
anemia NN I-NP O
. . O O
This DT B-NP O
resolved VBN B-VP O
with IN B-PP O
fluids NNS B-NP O
, , O O
blood NN B-NP O
tx NN I-NP O
, , O O
and CC O O
discontinuation NN B-NP O
of IN B-PP O
most JJS B-NP O
of IN B-PP O
her PRP$ B-NP O
BP NNP I-NP O
medications NNS I-NP O
. . O O
She PRP B-NP O
was VBD B-VP O
scheduled VBN I-VP O
for IN B-PP O
her PRP$ B-NP O
second JJ I-NP O
dose NN I-NP O
of IN B-PP O
gemcitabine NN B-NP O
on IN B-PP O
12/05 CD B-NP B-DATE
( -LRB- B-NP O
2 CD I-NP O
) -RRB- I-NP O
Diabetes NNP I-NP O
mellitus NN I-NP O
a DT B-NP O
. . B-VP O
Last JJ B-NP O
HgbA1c NNP I-NP O
= SYM O O
7.2 CD B-NP O
( -LRB- I-NP O
10/08/2097 CD I-NP B-DATE
) -RRB- O O
b NN B-NP O
. . O O
Was VBD B-VP O
maintained VBN I-VP O
on IN B-PP O
Glucophage NNP B-NP O
, , O O
but CC O O
this DT B-NP O
was VBD B-VP O
discontinued VBN I-VP O
2/2 CD B-NP O
worsening VBG B-VP O
renal JJ B-NP O
function NN I-NP O
c. NN B-NP O
Recently RB B-VP O
placed VBD I-VP O
on IN B-PP O
insulin NN B-NP O
with IN B-PP O
BS&#8217 CD B-NP O
;s NNS I-NP O
to TO B-VP O
be VB I-VP O
kept VBN I-VP O
around IN B-PP O
200 CD B-NP O
given VBN I-NP O
CA NNP I-NP O
dx NN I-NP O
HTN NNP B-NP O
( -LRB- I-NP O
TTE NN I-NP O
on IN B-PP O
11/11 CD B-NP B-DATE
showed VBD B-VP O
EF=69 DT B-NP O
% NN I-NP O
, , O O
no DT B-NP O
LVH) NN I-NP O
Chronic NNP B-NP O
renal JJ I-NP O
failure NN I-NP O
&#8211 CC I-NP O
; : O O
baseline NN B-NP O
creatinine CD I-NP O
1.8-2.2 CD O O
h/o NN B-NP O
BCC CC O O
h/o NN B-NP O
TIA NN I-NP O
MEDICATIONS NNS B-NP O
ON IN B-PP O
ADMISSION NNP B-NP O
: : O O
Vitamin NNP B-NP O
d VBD B-VP O
1000 CD B-NP O
units NNS I-NP O
po NN I-NP O
daily RB O O
Novolin NNP B-NP O
R NN I-NP O
innolet NN I-NP O
2-6 CC I-NP O
units NNS I-NP O
sc NN I-NP O
bid NN I-NP O
prn NN I-NP O
per IN B-PP O
sliding VBG B-NP O
scale NN I-NP O
Novolin NNP B-NP O
N NNP I-NP O
innolet NN I-NP O
22 CD B-NP O
units NNS I-NP O
sc NN I-NP O
qam NN I-NP O
ferrous JJ B-NP O
sulfate NN I-NP O
325mg JJ I-NP O
po NN I-NP O
daily RB O O
metoprolol NN B-NP O
25mg JJ I-NP O
po NN I-NP O
bid NN I-NP O
2 CD B-NP O
tabs NNS I-NP O
furosemide NN B-NP O
10mg CD I-NP O
po NN I-NP O
daily RB B-SBAR O
Ecotrin NNP B-NP O
325 CD I-NP O
mg NN I-NP O
po NN I-NP O
daily RB O O
Home NNP B-NP O
physical JJ I-NP O
therapy NN I-NP O
for IN B-PP O
strengthening VBG B-NP O
and CC I-NP O
ROM NNP I-NP O
generally RB B-ADVP O
. . B-VP O
Additionally RB B-ADVP O
L NNP B-NP O
shoulder NN I-NP O
ROM NNP I-NP O
and CC O O
strengthening VBG B-VP O
for IN B-PP O
frozen JJ B-NP O
shoulder NN I-NP O
. . O O
ALLERGIES NNS B-NP O
: : O O
NKDA NNP B-NP O
SOCIAL JJ B-NP O
HISTORY NN I-NP O
: : O O
Continues NNP B-NP O
to TO B-VP O
get VB I-VP O
out RP B-PRT O
to TO B-PP O
the DT B-NP O
American NNP I-NP B-ORGANIZATION
Senior NNP I-NP I-ORGANIZATION
Center NNP I-NP I-ORGANIZATION
, , O O
except IN B-PP O
on IN B-PP O
one CD B-NP O
day NN I-NP O
. . O O
Living VBG B-VP O
independently RB B-ADVP O
with IN B-PP O
supportive JJ B-NP O
family NN I-NP O
. . O O
Three CD B-NP O
daughters NNS I-NP O
and CC O O
2 CD B-NP O
sons NNS I-NP O
are VBP B-VP O
very RB B-ADJP O
involved VBN I-ADJP O
with IN B-PP O
her PRP B-NP O
. . O O
FAMILY NNP B-NP O
HISTORY NNP I-NP O
: : O O
She PRP B-NP O
was VBD B-VP O
born VBN I-VP O
in IN B-PP O
Arroyo NNP B-NP B-CITY
Grande NNP I-NP I-CITY
. . O O
She PRP B-NP O
had VBD B-VP O
five CD B-NP O
children NNS I-NP O
; : O O
four CD B-NP O
of IN B-ADVP O
them PRP B-NP O
are VBP B-VP O
alive JJ B-ADJP O
, , O O
all DT B-NP O
living VBG I-NP O
in IN B-PP O
the DT B-NP O
area NN I-NP O
. . B-NP O
Husband NN I-NP O
died VBD B-VP O
in IN B-PP O
2080 CD B-NP B-DATE
. . O O
Mother NNP B-NP O
had VBD B-VP O
Parkinson NNP B-NP O
's POS B-NP O
disease NN I-NP O
. . O O
Sister NN B-NP O
had VBD B-VP O
breast NN B-NP O
cancer NN I-NP O
at IN B-PP O
the DT B-NP O
age NN I-NP O
of IN B-PP O
72 CD B-NP B-AGE
. . O O
PHYSICAL NNP B-NP O
EXAM NNP I-NP O
: : O O
( -LRB- B-NP O
Exam NNP I-NP O
was VBD B-VP O
deferred VBN I-VP O
because IN B-PP O
patient NN B-NP O
was VBD B-VP O
taken VBN I-VP O
immediately RB B-ADVP O
to TO B-PP O
OR NN B-NP O
) -RRB- O O
VITALS NNS B-NP O
( -LRB- B-VP O
on IN B-PP O
arrival NN B-NP O
to TO B-PP O
floor NN B-NP O
) -RRB- I-NP O
: : O O
TEMP NNP B-NP O
: : O O
100.3 CD O O
HR NNP B-NP O
: : O O
62 CD O O
BP NNP B-NP O
: : O O
171/59 CD O O
RR NN B-NP O
: : O O
18 CD O O
O2SAT NN B-NP O
: : O O
98 CD B-NP O
% NN I-NP O
on IN B-PP O
RA NNP B-NP O
LABORATORY NNP B-NP O
DATA NNP I-NP O
: : O O
Chemistries NNS B-NP O
12/04/97 CD B-NP B-DATE
12/01/97 CD I-NP B-DATE
00:08 CD B-NP O
20:12 CD I-NP O
NA NNP B-NP O
130( JJ I-NP O
L NNP I-NP O
) -RRB- I-NP O
138 CD O O
K NNP B-NP O
4.3 CD I-NP O
4.8 CD O O
CL NN B-NP O
98( JJ I-NP O
L NNP I-NP O
) -RRB- I-NP O
104 CD O O
CO2 DT B-NP O
19.1( JJ I-NP O
L NNP I-NP O
) -RRB- I-NP O
22.8( JJ I-NP O
L NNP I-NP O
) -RRB- O O
BUN NNP B-NP O
60( CD I-NP O
H) NNP B-NP O
58( CD I-NP O
H) . O O
CRE NNP B-NP O
2.1( CD I-NP O
H) NNP B-NP O
2.2( CD I-NP O
H) . O O
GLU NNP B-NP O
381( CD I-NP O
H) NNP B-NP O
362( CD I-NP O
H) . O O
General NNP B-NP O
Chemistries NNPS I-NP O
Calcium NNP B-NP O
8.6 CD I-NP O
( -LRB- I-NP O
8.5-10.5 CD I-NP O
) -RRB- I-NP O
mg/dl . O O
Phosphorus NNP B-NP O
3.3 CD I-NP O
( -LRB- I-NP O
2.6-4.5 CD I-NP O
) -RRB- I-NP O
mg/dl . O O
Magnesium NNP B-NP O
1.6 CD I-NP O
( -LRB- O O
1.4-2.0) CD B-NP O
meq/L NN I-NP O
Liver NN B-NP O
Function NNP I-NP O
Tests . O O
Total JJ B-NP O
Protein NNP I-NP O
7.1 CD I-NP O
( -LRB- I-NP O
6.0-8.3 CD I-NP O
) -RRB- I-NP O
g/dl . O O
Albumin NNP B-NP O
3.6 CD I-NP O
( -LRB- I-NP O
3.3-5.0) NN I-NP O
g/dl NN I-NP O
Globulin NNP B-NP O
3.5 CD I-NP O
( -LRB- I-NP O
2.6-4.1 CD B-NP O
) -RRB- I-NP O
g/dl . O O
Total JJ B-NP O
Bilirubin NNP I-NP O
0.8 CD I-NP O
( -LRB- O O
0.0-1.0) CD B-NP O
mg/dl NN I-NP O
Alkaline NNP B-NP O
Phosphatase NNP I-NP O
84 CD I-NP O
( -LRB- I-NP O
30-100 CD I-NP O
) -RRB- I-NP O
U/L . O O
Transaminase-SGPT NNP B-NP O
15 CD I-NP O
(7-30 CD I-NP O
) -RRB- I-NP O
U/L . O O
Transaminase-SGOT JJ B-NP O
19 CD I-NP O
( -LRB- I-NP O
9-32 CD I-NP O
) -RRB- I-NP O
U/L . O O
CBC NNP B-NP O
: : O O
WBC NNP B-NP O
10.8 CD I-NP O
( -LRB- I-NP O
4.5-11.0) JJ I-NP O
th/cmm NN I-NP O
HCT NNP B-NP O
27.3 CD I-NP O
L NNP I-NP O
( -LRB- I-NP O
36.0-46.0) CD I-NP O
% NN I-NP O
HGB NNP B-NP O
9.5 CD I-NP O
L NNP I-NP O
( -LRB- I-NP O
12.0-16.0) JJ I-NP O
gm/dl NN I-NP O
RBC NNP B-NP O
3.07 CD I-NP O
L NNP I-NP O
( -LRB- I-NP O
4.00-5.20 CD I-NP O
) -RRB- I-NP O
mil/cmm . O O
PLT NNP B-NP O
351 CD I-NP O
H NNP I-NP O
( -LRB- I-NP O
150-350 CD I-NP O
) -RRB- I-NP O
th/cumm . O O
MCV NN B-NP O
89 CD I-NP O
( -LRB- I-NP O
80-100 CD B-PP O
) -RRB- B-NP O
fl NN I-NP O
MCH NNP B-NP O
31.0 CD I-NP O
( -LRB- I-NP O
26.0-34.0) JJ I-NP O
pg/rbc NN I-NP O
MCHC NNP B-NP O
34.8 CD I-NP O
( -LRB- O O
31.0-37.0) CD B-NP O
g/dl NN I-NP O
RDW NNP B-NP O
16.0 CD I-NP O
H NNP I-NP O
( -LRB- I-NP O
11.5-14.5 CD I-NP O
) -RRB- B-NP O
% NN I-NP O
DIFFERENTIAL NNP B-NP O
REQUEST NNP I-NP O
RECEIVED NNP I-NP O
Diff JJ B-NP O
Method NNP I-NP O
Auto NN I-NP O
Poly NNP B-NP O
82 CD I-NP O
H NNP I-NP O
( -LRB- I-NP O
40-70 CD I-NP O
) -RRB- B-NP O
% NN I-NP O
Lymphs NNP B-NP O
10 CD I-NP O
L NNP I-NP O
( -LRB- I-NP O
22-44 CD I-NP O
) -RRB- B-NP O
% NN I-NP O
Monos NNP B-NP O
6 CD I-NP O
( -LRB- I-NP O
4-11 CD I-NP O
) -RRB- B-NP O
% NN I-NP O
EOS NNS B-NP O
1 CD B-NP O
(0-8 CD I-NP O
) -RRB- O O
% NN O O
Basos NNS B-NP O
1 CD B-NP O
(0-3 JJ I-NP O
) -RRB- I-NP O
% NN I-NP O
Absolute JJ B-NP O
Neuts NNP I-NP O
8.92 CD I-NP O
H NNP I-NP O
( -LRB- I-NP O
1.8-7.7 CD I-NP O
) -RRB- I-NP O
th/cmm . O O
Absolute JJ B-NP O
Lymphs NNP I-NP O
1.00 CD I-NP O
( -LRB- I-NP O
1.0-4.8 CD I-NP O
) -RRB- I-NP O
th/cmm . O O
Absolute JJ B-NP O
Monos NNP I-NP O
0.63 CD I-NP O
H NNP I-NP O
( -LRB- I-NP O
0.2-0.4 CD I-NP O
) -RRB- I-NP O
th/cmm . O O
Absolute JJ B-NP O
EOS NNP I-NP O
0.14 CD I-NP O
( -LRB- I-NP O
0.1-0.3 CD I-NP O
) -RRB- I-NP O
th/cmm . O O
Absolute JJ B-NP O
Basos NNP I-NP O
0.07 CD I-NP O
( -LRB- I-NP O
0.0-0.3 CD I-NP O
) -RRB- I-NP O
th/cmm . O O
Aniso NNP B-NP O
1+ CD I-NP O
H NNP I-NP O
( -LRB- I-NP O
None NN I-NP O
) -RRB- O O
Hypo NNP B-NP O
None NN I-NP O
( -LRB- I-NP O
None NN I-NP O
) -RRB- O O
Macrocytes NNP B-NP O
None NN I-NP O
( -LRB- I-NP O
None NN I-NP O
) -RRB- O O
Microcytes NNS B-NP O
None NN B-VP O
( -LRB- B-NP O
None NN I-NP O
) -RRB- O O
Coagulation NNP B-NP O
Studies NNPS I-NP O
Superstat NNP B-NP O
PT NNP I-NP O
12.9 CD I-NP O
( -LRB- I-NP O
10.3-13.2 CD B-PP O
) -RRB- B-NP O
sec NN I-NP O
Superstat NNP B-NP O
PT-INR NNP I-NP O
1.1 CD O O
Superstat NNP B-NP O
APTT NNP I-NP O
20.6 CD I-NP O
L NNP I-NP O
( -LRB- I-NP O
22.1-34.0) JJ I-NP O
sec NN I-NP O
STUDIES NNS B-NP O
: : O O
Plain JJ B-NP O
Films NNP I-NP O
: : O O
FINDINGS NNS B-NP O
: : O O
Right RB B-NP O
hip NN I-NP O
: : O O
There EX B-NP O
is VBZ B-VP O
a DT B-NP O
transverse NN I-NP O
transcervical JJ I-NP O
fracture NN I-NP O
through IN B-PP O
the DT B-NP O
sphenoid NN I-NP O
. . O O
There EX B-NP O
is VBZ B-VP O
lateral JJ B-NP O
superior JJ I-NP O
displacement NN I-NP O
of IN B-PP O
the DT O O
distal JJ B-NP O
segment NN I-NP O
. . O O
There EX B-NP O
is VBZ B-VP O
no DT B-NP O
evidence NN I-NP O
of IN B-PP O
dislocation NN B-NP O
. . O O
Pelvis NNP B-NP O
: : O O
There EX B-NP O
is VBZ B-VP O
diffuse JJ B-NP O
osteopenia NN I-NP O
involving VBG B-VP O
the DT B-NP O
pelvis NN I-NP O
. . O O
Again RB O O
noted VBN B-NP O
is VBZ B-VP O
a DT B-NP O
transcervical JJ I-NP O
fracture NN I-NP O
to TO B-PP O
the DT B-NP O
right JJ I-NP O
femur NN I-NP O
. . O O
There EX O O
is VBZ O O
superior JJ B-NP O
lateral JJ I-NP O
displacement NN I-NP O
of IN B-PP O
the DT B-NP O
distal JJ I-NP O
fracture NN I-NP O
segment NN I-NP O
. . O O
The DT O O
sacrum NN B-NP O
is VBZ B-VP O
not RB I-VP O
well RB I-VP O
seen VBN I-VP O
secondary JJ B-ADJP O
to TO B-PP O
overlying VBG B-VP O
bowel NN B-NP O
gas NN I-NP O
. . O O
Minimal '' O O
degenerative JJ B-NP O
changes NNS I-NP O
of IN B-PP O
the DT B-NP O
lumbar NN I-NP O
spine NN I-NP O
are VBP B-VP O
noted VBN I-VP O
. . O O
Shoulder NNP B-NP O
: : O O
There EX B-NP O
is VBZ B-VP O
no DT B-NP O
evidence NN I-NP O
of IN B-PP O
left JJ B-NP O
shoulder NN I-NP O
dislocation NN I-NP O
or CC O O
acute JJ B-NP O
fracture NN I-NP O
. . O O
The DT B-NP O
visualized VBN I-NP O
lung NN I-NP O
fields NNS I-NP O
and CC I-NP O
ribs NNS I-NP O
are VBP B-VP O
intact JJ B-ADJP O
. . O O
There EX B-NP O
is VBZ B-VP O
minimal JJ B-NP O
degenerative NN I-NP O
change NN I-NP O
involving VBG B-VP O
the DT B-NP O
left NN I-NP O
a.c. . O O
joint JJ B-ADJP O
. . O O
Chest NNP B-NP O
: : O O
Comparison NNP B-NP O
to TO B-PP O
10/31/97 CD B-NP B-DATE
. . O O
Multiple NNP B-VP O
pulmonary JJ B-NP O
nodules NNS I-NP O
are VBP B-LST O
noted VBN B-VP O
. . O O
There EX B-NP O
is VBZ B-VP O
no DT B-NP O
evidence NN I-NP O
of IN B-PP O
focal JJ B-NP O
consolidation NN I-NP O
or CC O O
pulmonary NN B-NP O
edema NN B-NP O
. . O O
No DT B-NP O
large JJ I-NP O
pleural JJ I-NP O
effusion NN I-NP O
or CC O O
appreciable JJ B-NP O
pneumothorax NN I-NP O
is VBZ B-LST O
identified VBN B-VP O
. . B-PP O
The DT B-NP O
cardiomediastinal JJ I-NP O
silhouette NN I-NP O
is VBZ B-VP O
stable JJ B-ADJP O
. . O O
Degenerative JJ B-NP O
changes NNS I-NP O
of IN B-PP O
the DT B-NP O
thoracic JJ I-NP O
spine NN I-NP O
are VBP B-VP O
noted VBN I-VP O
. . O O
IMPRESSION NN B-NP O
: : O O
Right RB B-ADVP O
transcervical JJ B-NP O
femoral JJ I-NP O
fracture NN I-NP O
. . O O
No DT B-NP O
evidence NN I-NP O
of IN B-PP O
dislocation NN B-NP O
. . O O
No DT B-NP O
evidence NN I-NP O
of IN B-PP O
shoulder NN B-NP O
dislocation NN I-NP O
. . O O
Multiple JJ B-NP O
pulmonary NN I-NP O
nodules NNS I-NP O
consistent JJ B-ADJP O
with IN B-PP O
metastatic JJ B-NP O
disease NN I-NP O
. . O O
FINDINGS NNS B-NP O
: : O O
Previously RB B-ADVP O
noted VBD B-VP O
minimally RB I-VP O
displaced VBN I-VP O
right JJ B-NP O
hip NN I-NP O
fracture NN I-NP O
. . O O
Osteoarthrosis NNP B-NP O
of IN B-PP O
the DT B-NP O
knee NN I-NP O
. . O O
Soft NNP B-NP O
tissues NNS I-NP O
swelling VBG B-VP O
along IN B-PP O
the DT B-NP O
medial JJ I-NP O
aspect NN B-NP O
of IN B-PP O
the DT B-NP O
knee NN I-NP O
is VBZ B-VP O
noted VBN I-VP O
. . O O
There EX B-NP O
are VBP B-VP O
vascular JJ B-NP O
calcifications NNS I-NP O
. . O O
Generalized NNP B-NP O
osteopenia NN I-NP O
. . O O
IMPRESSION NN B-NP O
: : O O
Right RB B-ADVP O
hip NN B-VP O
fracture NN B-NP O
as IN B-PP O
previously RB B-NP O
described VBN I-NP O
. . I-NP O
Osteoarthrosis NNP I-NP O
of IN B-PP O
the DT B-NP O
knee NN B-NP O
. . O O
EKG NNP B-NP O
: : O O
Sinus NNP B-NP O
bradycardia NN I-NP O
. . O O
ASSESSMENT NNP B-NP O
&amp; NNP I-NP O
PLAN NNP I-NP O
: : O O
87 CD B-NP B-AGE
yo NNP I-NP O
F NNP I-NP O
with IN B-PP O
h/o PRP$ B-NP O
metastatic JJ I-NP O
pancreatic JJ I-NP O
CA NNP I-NP O
s/p NN I-NP O
1 CD B-NP O
dose NN I-NP O
of IN B-PP O
gemcitabine NN B-NP O
and CC I-NP O
biliary NN I-NP O
stenting NN I-NP O
, , O O
CKD NNP B-NP O
, , O O
DM NNP B-NP O
, , O O
and CC O O
HTN NNP B-NP O
who WP B-NP O
p/w RB I-NP O
right JJ I-NP O
hip NN I-NP O
fracture NN I-NP O
s/p VBD B-VP O
mechanical JJ B-NP O
fall NN I-NP O
at IN B-PP O
home NN B-NP O
. . O O
The DT B-NP O
plan NN I-NP O
of IN B-PP O
care NN B-NP O
by IN B-PP O
issue NN B-NP O
is VBZ B-VP O
as IN B-SBAR O
follows VBZ B-VP O
: : O O
( -LRB- B-NP O
1 CD I-NP O
) -RRB- I-NP O
Right RB I-NP O
hip NN I-NP O
fracture NN I-NP O
: : O O
Patient NNP B-NP O
will MD B-VP O
require VB I-VP O
post-operative JJ B-NP O
anti-coagulation NN I-NP O
. . O O
Patient NNP B-NP O
is VBZ B-VP O
undergoing VBG I-VP O
high-risk JJ B-NP O
procedure NN I-NP O
and CC O O
is VBZ B-VP O
also RB B-ADVP O
at IN B-PP O
increased VBN B-NP O
risk NN I-NP O
for IN B-PP O
VTE NN B-NP O
given VBN I-NP O
cancer NN I-NP O
dx NN I-NP O
. . O O
According VBG B-PP O
to TO B-PP O
guidelines NNS B-NP O
from IN B-PP O
ACCP NNP B-NP O
: : O O
# # B-NP O
UFH NNP I-NP O
5000 CD I-NP O
Units NNS I-NP O
SC VBP B-VP O
TID NNP B-NP O
[or NNP I-NP O
LMWH NNP I-NP O
&gt CC O O
;3400 CD B-NP O
Units NNS I-NP O
SC VBP B-VP O
QD NNP B-NP O
( -LRB- B-VP O
her PRP$ B-NP O
CrCl NNP I-NP O
&lt NNP I-NP O
;30 CD I-NP O
, , O O
therefore RB B-VP O
renally RB I-VP O
dosed VBN I-VP O
= SYM O O
LMWH NNP B-NP O
30mg CD I-NP O
SC NNP I-NP O
QD) NNP I-NP O
] VBD B-VP O
to TO I-VP O
be VB I-VP O
started VBN I-VP O
either RB B-ADVP O
in IN B-PP O
PACU NNP B-NP O
or CC O O
on IN B-PP O
the DT B-NP O
floor NN I-NP O
. . O O
# # B-NP O
Compression NNP I-NP O
stockings NNS I-NP O
# # B-NP O
Pneumo-boots NNS I-NP O
# # B-NP O
Plan NNP I-NP O
to TO B-VP O
continue VB I-VP O
VTE JJ B-NP O
prophylaxis NNS I-NP O
for IN B-PP O
4-6 CD B-NP O
weeks NNS I-NP O
post-op . O O
# # B-NP O
Encourage NNP I-NP O
ambulation NN I-NP O
as RB B-ADVP O
soon RB I-ADVP O
as IN B-SBAR O
tolerated VBN B-VP O
( -LRB- B-NP O
per IN B-PP O
ortho NN B-NP O
, , O O
pt NN B-NP O
might MD B-VP O
be VB I-VP O
ambulatory JJ B-ADJP O
as RB B-ADVP O
soon RB I-ADVP O
as IN B-SBAR O
tomorrow NN B-NP O
) -RRB- O O
( -LRB- B-NP O
2 CD I-NP O
) -RRB- B-ADVP O
DM . O O
Patient NNP B-NP O
recently RB B-ADVP O
started VBD B-VP O
on IN B-PP O
insulin NN B-NP O
at IN B-PP O
home NN B-NP O
. . O O
Will MD B-VP O
continue VB I-VP O
half DT B-NP O
dose NN I-NP O
of IN B-PP O
home NN B-NP O
insulin NN I-NP O
with IN B-PP O
IVF NNP B-NP O
with IN B-PP O
glucose NN B-NP O
. . O O
# # B-NP O
RISS NNP I-NP O
, , O O
until IN B-PP O
tolerating VBG B-NP O
POs NNS I-NP O
, , O O
then RB B-ADVP O
restart VB B-VP O
normal JJ B-NP O
insulin NN I-NP O
. . O O
( -LRB- B-NP O
3 CD I-NP O
) -RRB- I-NP O
Dispo . O O
Plan NNP B-ADJP O
to TO B-VP O
D/C NNP B-NP O
when WRB B-ADVP O
clinically RB B-NP O
stable JJ I-NP O
post-op NN I-NP O
. . O O
Per IN B-PP O
PCP NNP B-NP O
, , O O
patient NN B-NP O
would MD B-VP O
like VB I-VP O
to TO I-VP O
return VB I-VP O
directly RB B-NP O
home NN I-NP O
after IN B-PP O
surgery NN B-NP O
without IN B-PP O
rehab NN B-NP O
( -LRB- I-NP O
home NN I-NP O
rehab NN I-NP O
) -RRB- O O
. . B-NP O
Family NNP I-NP O
notes VBZ B-VP O
that IN B-SBAR O
patient NN B-NP O
currently RB B-ADVP O
lives VBZ B-VP O
at IN B-PP O
daughter NN B-NP O
&#8217 CD I-NP O
;s NNS I-NP O
home NN B-ADVP O
where WRB B-ADVP O
there EX B-NP O
are VBP B-VP O
many JJ B-NP O
steps NNS I-NP O
which WDT B-NP O
would MD B-VP O
make VB I-VP O
home NN B-NP O
rehab NN I-NP O
difficult JJ B-ADJP O
. . O O
# # B-NP O
Consider VB B-VP O
rehab VBG I-VP O
placement NN B-NP O
, , O O
follow-up JJ B-NP O
attending VBG I-NP O
recs NNS I-NP O
, , O O
discuss VB B-VP O
with IN B-PP O
family NN B-NP O
in IN B-PP O
AM NNP O O
Brandon NNP B-NP B-DOCTOR
Hale NNP I-NP I-DOCTOR
EFS NNS B-NP B-HOSPITAL
III NNP I-NP O
, , O O
Internal NNP B-NP O
Medicine NNP I-NP O
Pager NNP B-NP O
# # I-NP O
28913 CD O B-PHONE
ADDENDUM: . O O
Case NNP B-NP O
and CC I-NP O
plan NN I-NP O
discussed VBN B-VP O
and CC I-VP O
incorporated VBN I-VP O
into IN B-PP O
this DT B-NP O
excellent JJ I-NP O
EFS NNS I-NP B-HOSPITAL
III NNP I-NP O
Note NNP I-NP O
. . O O
Fred NNP B-NP B-DOCTOR
Allen NNP I-NP I-DOCTOR
, , O O
M.D. NNP B-NP O
Medicine NNP B-NP O
PGY1 CD I-NP O
Pager NNP B-NP O
# # I-NP O
80817 CD O B-PHONE
